Technologieangebote

Pharmaceutical Composition for the Treatment of Solar Urticaria

We offer a lidocaine/prilocaine combination for the treatment or prevention of solar urticaria. Up to now the lidocaine/prilocaine combination is used for dermal anesthesia (marketed as EMLA®). The inventors demonstrated in two of two patients with solar urticaria and an action spectrum to UVA that the combination of lidocaine and prilocaine protects the tissue and inhibits triggering of the cascade which usually leads to typical symptoms of solar urticaria.

The topical application of a lidocaine/prilocaine mixture prior to UV-provocation stabilizes or inhibits sensory nerve fibres of the skin and induces down-regulation or inhibition of the release of pro-inflammatory neuropeptides. Due to this more general concept it is assumed that (1) other local anesthetics in addition to lidocaine and prilocaine, (2) lidocaine alone or prilocaine alone, and (3) lidocaine and/or prilocaine in combination with other local anesthetics are effective as well.

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Ursula Haufe

Kommentare (0)

Schreiben Sie einen Kommentar